Hagedorn Research Institute (HRI) in Gentofte, Denmark is a fully integrated part of Novo Nordisk. From 2010, HRI are expanding the scope with early applied research in addition to our established sphere, basic research. Five decades of world-class basic research is combined with a maximised ability to translate science into better treatment for people with diabetes. That makes HRI the market leading incubator for innovation to change diabetes.
At the core of the new scope is our effort to identify new biology-based targets for potential drugs to feed Novo Nordisk’s pipeline within the key areas of diabetes pathogenesis, treatment and cure. The discovery primarily takes place through in vitro assays with proteins and peptides. With our new scope, we serve as early applied research centre for Novo Nordisk’s Diabetes Research Unit (DRU) and as a strategic hub for DRU’s early discovery research - with a shared roadmap for how activities can generate new projects.
Our vision is to find a cure for diabetes and its complications, to identify new opportunities for treating diabetes and to establish HRI as a world-class early applied research centre. We will do so by constantly providing Novo Nordisk with pre-projects driven by early research in our 5 specialist areas: insulin and incretin biology, stem cell biology, beta cell regeneration, diabetes inflammation and diabetes genetics. Also, we will continuously participate in scientific networks and collaborate with academia, top scientists and institutions and publish our research.
We have a strong focus on developing new talents that will lead us further towards our aspiration. Working at HRI means working in a highly innovative and dynamic matrix organisation where state-of-the-art research and teamwork go hand in hand – and where the agenda can quickly change. This calls for people with a flexible mindset and the ability to quickly adjust to new tasks and new team formations.
At HRI, you will meet a welcoming environment where scientists, post docs, PhD students, master students, research technicians and supportive staff all work together on preventing, treating and defeating diabetes - and, by this means, improving the quality of life for millions of people around the world.
HAGEDORN RESEARCH INSTITUTE HISTORY
Shortly after the discovery of insulin by Banting and Best in 1921, Professor August Krogh (1874-1949), Nobel Laureate in Physiology, and Dr. Hans Christian Hagedorn (1888-1971), a young diabetologist, obtained the rights from the discoverers in Toronto to produce insulin for the diabetics in Scandinavia.This formed the basis for the establishment of Nordisk Insulinlaboratorium in 1923.That same year, the Nordisk Insulin Foundation was inaugurated, to support research within physiology and endocrinology, especially ...